The UCSF Department of Urology is committed to offering the highest quality urologic care and innovative research programs. The following studies are taking place in our department's clinical trials office. If interested to join any of the studies, please call 415-514-0554 or email: [email protected]
(Your participation in a clinical trial is voluntary. The information you provide will be confidential, and individual information will not be released.)
Exercise may delay prostate cancer progression
UCSF investigators have reported that brisk walking or other aerobic exercise and intake of specific foods may delay or deter progression of prostate cancer. To expand on these exciting results, we are conducting research to examine whether personalized exercise and diet programs alter prostate cancer biology or reduce the risk of progression.
AS Exercise RCT: A Randomized Clinical Trial of Exercise versus Usual Care among Men Opting for Active Surveillance for Prostate Cancer
We are conducting a clinical trial of tailored exercise for men choosing active surveillance for early stage/low grade prostate cancer. This study is open to men who are on Active Surveillance for localized prostate cancer. Participants assigned to the intervention will receive a four-month home-based personalized exercise prescription, free exercise coaching, and a heart-rate monitor. Participants will be asked to come on site 2-3 times; those who complete all study assessments may earn up to $500.
AS Exercise Observational Study: An Observational Study of Exercise among Men Opting for Active Surveillance for Prostate Cancer
We are conducting a study of cardiopulmonary fitness among men choosing active surveillance for early stage/low grade prostate cancer. This study is open to men who are on Active Surveillance for localized prostate cancer. Participants who complete the one-time study assessment will receive $100.
CHAMP: A randomized Controlled trial of High-intensity Aerobic and resistance exercise for Metastatic Prostate cancer
We are conducting a clinical trial of tailored exercise for men with metastatic castrate-resistant prostate cancer. This study will enroll prostate cancer patients with metastases while on standard hormonal therapy but with little to no symptoms. Participants assigned to an intervention group (aerobic or resistance exercise) will receive a three-month personalized exercise prescription and can opt for supervised exercise with an exercise specialist or remote exercise at a local gym (with remote monitoring by an exercise specialist). All participants will receive a consultation with an exercise specialist; those who complete all study assessments may earn up to $100.
Questions? Ready to Join? If you have questions or are interested to join any of the above studies, please call 415-514-0554 or email: [email protected]
(please call us or check back for further info)
Prostate 8 Study - II: A Randomized Controlled Trial of Diet & Exercise Interventions among Men with Prostate Cancer – II
Our UCSF research team has developed diet and exercise programs specifically geared toward men with prostate cancer. The purpose of this study is to determine whether a 2-year wellness program focused on diet and exercise improves biological, clinical, and quality of life outcomes in men choosing surgery as primary treatment for prostate cancer. Men will enroll 6-8 weeks prior to radical prostatectomy and are followed for 2 years. If you participate in this study you will be randomly assigned to one of four study groups that will receive different educational and supportive tools. At different points in the study, all men will receive print educational materials about the benefits of exercise and diet for men with prostate cancer, a personalized lifestyle report, heart rate monitor and resistance bands to use during exercise, and a 9-week text messaging program focused on your recovery after radical prostatectomy surgery. Those who complete all study assessments may earn up to $250. The study plans to open in January 2018.
INTERVAL – a supervised exercise trial for men with metastatic castrate resistant prostate cancer
CLASS – an observational study consisting of surveys about lifestyle and quality of life, with options to donate biospecimens and digital app data (e.g., Fitbit, MyFitnessPal, Apple Healthkit)
TrueNth, Community of Wellness – a clinical trial to see if interactive web-site based tools help men with prostate cancer adopt healthy habits, conducted nationally and developed in collaboration with Oregon Health Sciences University
Please consider volunteering for research and tell your friends!
Studies brought to you by the Chan Lifestyle Team, specializing in epidemiologic & translational lifestyle research.
Current Team members:
June M. Chan, ScD, Professor (lead for ASX, CLASS, TrueNth Community of Wellness)
Stacey A. Kenfield, ScD, Associate Professor (lead for CHAMP, Prostate 8)
Erin L. Van Blarigan, ScD, Assistant Professor (see Dr. Van Blarigan’s studies in Gastro-intestinal Oncology)
Students, Fellows, Residents
Scott Bauer, MD, Resident, UCSF
Crystal Langlais, epidemiology PhD student, UCSF
Benjamin Cedars, medical student, Thomas Jefferson University
Lucy Tantum, college student, Dartmouth University
David Tat, medical student, Duke University (departed)
Vivian Liu, college student, UC Berkeley (departed)
Kyle Zuniga, medical student Columbia University, UCSF Osher Center fellow (2018-2019)
Main Clinical Research Coordinator: Emil Lavaki
In collaboration with: UCSF Depts. of Urology, Epidemiology & Biostatistics, Pathology, Medicine (including Division of Hematology/Oncology), Physical Therapy and Rehabilitation Science, Orthopedic Surgery, Radiation Oncology; and Urologic Clinical and Translational Science staff (Dept. of Urology); Children’s Hospital Oakland Research Institute; UCSF Osher Center for Integrative Medicine; & the UCSF Helen Diller Family Comprehensive Cancer Center. External Collaborators: Oregon Health Sciences University, Memorial Sloan Kettering Cancer Center, Harvard T.H. Chan School of Public Health, & Edith Cowan University (Australia).
Acknowledgements: National Institutes of Health/National Cancer Institute, Department of Defense, Helen Diller Family Chair in Population Science for Urologic Cancer, Steven & Christine Burd Safeway Distinguished Professorship, GenomeDx, Movember Foundation, Prostate Cancer Foundation.
We are indebted to all the study participants! Thank You!